Botanix Pharmaceuticals Limited announced updates to its Board composition, with Matt Callahan re-joining the company's Board as an Executive Director and Rob Towner stepping down from his role as Non-Executive Director. Mr. Callahan's return comes at a time as the Company continues to progress multiple clinical development programs including: preparing for the end of Phase 2 meeting with the FDA (BTX 1503 Phase 2 acne study), nearing the completion of the BTX 1204 Phase 2 atopic dermatitis study, recent commencement of the new Phase 1b rosacea study and its antimicrobial product (BTX 1801) expected to enter Phase 2 clinical study in the near term. The Date of appointment of Mathew Callahan is 10 February 2020.